Rigel Pharma (RIGL) Misses Q3 EPS by 2c
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $48.67 +0.35%
Revenue Growth %: +15.2%
Financial Fact:
General and administrative: 4.56M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +15.2%
Financial Fact:
General and administrative: 4.56M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q3 EPS of ($0.12), $0.02 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $21.5 million versus the consensus estimate of $23.56 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- JPMorgan Upgrades Whitehaven Coal Ltd. (WHC:AU) (WHITF) to Overweight
- Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
